Grace Therapeutics (GRCE)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	11.06 mm	11.06 mm	11.06 mm	11.06 mm	11.06 mm	11.06 mm
Cash burn (monthly)	1.37 mm	624.17 k	1.59 mm	1.55 mm	1.37 mm	1.17 mm
Cash used (since last report)	3.16 mm	1.44 mm	3.67 mm	3.58 mm	3.17 mm	2.70 mm
Cash remaining	7.90 mm	9.61 mm	7.39 mm	7.47 mm	7.89 mm	8.35 mm
Runway (months of cash)	5.8	15.4	4.7	4.8	5.7	7.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

GRCE institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0.00	0.00
Total shares	0.00	0.00
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

GRCE insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 May 24	Amresh Kumar	Stock Options Class A Common Shares	Grant	Acquire A	No	No	2.96	19,740	58.43 k	19,740
6 May 24	DelAversano Robert J	Stock Options Class A Common Shares	Grant	Acquire A	No	No	2.96	4,500	13.32 k	4,500
6 May 24	Prashant Kohli	Stock Options Class A Common Shares	Grant	Acquire A	No	No	2.96	128,770	381.16 k	128,770

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Grace Therapeutics, Maintains $12 Price Target

18 Feb 25

HC Wainwright & Co. analyst Oren Livnat reiterates Grace Therapeutics (NASDAQ:GRCE) with a Buy and maintains $12 price target.

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

10 Feb 25

Grace Therapeutics' GTx-104 met its Phase 3 trial endpoint, showing clinical benefits over oral nimodipine. US NDA submission is expected in early 2025.

Press releases

From Benzinga Pro

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

10 Feb 25

Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential to receive up to an

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

10 Feb 25

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRINCETON, N.J., Feb.